Advanced Diagnostic Laboratories News
Advanced Diagnostic Laboratories Awarded Grant to Evaluate Drug-Susceptibility Testing Methods for Mycobacterium Tuberculosis Complex
National Jewish Health Advanced Diagnostic Laboratories has been selected to evaluate first- and second-line drug-susceptibility testing for Mycobacterium tuberculosis complex (MTBC), the bacteria that cause tuberculosis (TB). The laboratories will evaluate two methods: the Indirect Agar Proportion and the BD BACTEC MGIT Mycobacterial Detection System.
ISO 15189 Accreditation from CAP Renewed
The College of American Pathologists (CAP) has renewed CAP 15189SM Accreditation for National Jewish Health® Advanced Diagnostic Laboratories. Currently, only 22 laboratories in the United States have earned this prestigious accreditation based on ISO 15189.
New Molecular Assays Identify NTM
National Jewish Health Advanced Diagnostic Laboratories is now utilizing molecular assays, including rpoB and 16S rRNA gene sequencing, to identify nontuberculous mycobacteria (NTM) and other organisms.
Dr. Max Salfinger Joins ADx Laboratories
National Jewish Health Advanced Diagnostic Laboratories Laboratory Director recently welcomed Max Salfinger, MD, FAAM, FIDSA, as the new mycobacteriology laboratory director.
Pulmonary Mycobacterium Avium Complex Disease Treatment Review
Advanced Diagnostic Laboratories was published in the American Journal of Respiratory and Critical Care Medicine on June 28, 2012. The article entitled "The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium Avium Complex Disease Treatment" looks to explain the poor outcomes of currently recommended treatment regimens for Mycobacterium avium complex (MAC) lung disease.
Dr. Ashley Frazer-Abel Contributes to Emerging Knowledge of Hereditary Angioedema
Ashley Frazer-Abel, Ph.D. participated in a scientific workshop attended by the world’s leading experts on hereditary angioedema (HAE) in April 2012. HAE is a familial condition that causes attacks of severe and often painful swelling throughout the body. The newest type of HAE, HAE Type III, is characterized by normal level and function of C1-inhibitor, a circulating complement protein that is deficient in HAE Type I and II patients. The workshop brought together international experts in angioedema researchers and clinical treatment with the objective of clarifying the current knowledge of Type III HAE, defining the gaps in our knowledge, and coming to a consensus on what characterizes this emerging clinical syndrome.As an expert in complementology, Dr. Frazer-Abel was the only invited laboratorian and as such served as consultant to attendees on how new HAE Type III research can best be translated into clinical diagnostic tests.
Dr. Leonid Heifets Retires
After a distinguished academic and clinical career, Professor Leonid Heifets MD, PhD, DSc, has elected to retire from his operational responsibilities within the Advanced Diagnostic Laboratories.
Dr. Heifets started his career at National Jewish Health in 1979 and authored more than 200 papers in the field of epidemiology and microbiology of infectious diseases. He received international recognition from his peers, having become a recipient of the Lifetime Achievement Award from the International Union against Tuberculosis and Lung disease in 2009 for his contribution to medicine.